Next Financial Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
– Sell
-2,250
Closed -$6K – 2448
2016
Q4
$6K Hold
2,250
– – ﹤0.01% 1891
2016
Q3
$7K Buy
2,250
+1,250
+125% +$3.9K ﹤0.01% 1831
2016
Q2
$3K Hold
1,000
– – ﹤0.01% 1547
2016
Q1
$3K Hold
1,000
– – ﹤0.01% 1501
2015
Q4
$4K Hold
1,000
– – ﹤0.01% 1484
2015
Q3
$4K Hold
1,000
– – ﹤0.01% 1515
2015
Q2
$5K Hold
1,000
– – ﹤0.01% 1504
2015
Q1
$6K Hold
1,000
– – ﹤0.01% 1455
2014
Q4
$6K Hold
1,000
– – ﹤0.01% 1456
2014
Q3
$6K Hold
1,000
– – ﹤0.01% 2007
2014
Q2
$7K Buy
+1,000
New +$11.3K ﹤0.01% 862

Other funds holding ECYT

Next Financial Group's ECYT Position: Q1 2017 in Review

Next Financial Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2017, closing a stake of 2,250 shares — an estimated $6K sold.

Next Financial Group first reported a position in ECYT in Q2 2014 and held it in 11 quarters. The position peaked at $7K in Q3 2016. 82 funds tracked by Wall St. Rank hold ECYT as of Q1 2017.

  • Next Financial Group reported no remaining Endocyte, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Next Financial Group sold 2,250 Endocyte, Inc. Common Stock shares in Q1 2017, an estimated $6K.
  • Next Financial Group first reported a position in Endocyte, Inc. Common Stock in Q2 2014 and held it in 11 quarters.
  • Next Financial Group's Endocyte, Inc. Common Stock position peaked at $7K in Q3 2016.
  • 82 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2017.

Based on Next Financial Group's 13F filing for Q1 2017, filed 8 May 2017.